The Claim
Transient rapamycin treatment administered for as little as 8 weeks in late-life mice results in improved diastolic heart function, with these benefits persisting for at least 8 weeks post-treatment cessation despite metabolic parameters returning to baseline levels.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Giving old mice the drug rapamycin for just 8 weeks made their hearts work better at filling with blood, and this improvement lasted at least 8 weeks after stopping the drug—even though other metabolic measurements went back to normal.
See the scientific wording
Transient rapamycin treatment lasting as short as 8 weeks administered late in life can improve diastolic heart function in mice, with benefits persisting for at least 8 weeks after treatment cessation even after metabolic parameters return to baseline.
What the research says
1 studyStudy: Transient and late-life rapamycin for healthspan extension
The study is about giving rapamycin to older mice to see if it helps healthspan, but the abstract doesn't mention anything about heart function or the specific timing details in the claim, so we can't tell if it supports or contradicts the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.